What is the difference between Sermorelin and Tesamorelin?

Both are GHRH-receptor analogs, but Sermorelin is the 29-residue GHRH fragment while Tesamorelin is a longer 44-residue analog with a stabilizing N-terminal modification for improved research half-life. They act on the same receptor and differ in length, stability, and regulatory history. Both are for research use only.

Do Sermorelin and Tesamorelin act on the same receptor?

Yes. Both are studied as agonists of the GHRH receptor within the somatotropic axis, differing in fragment length and stability rather than in target receptor. Neither is approved for human use.

Is Tesamorelin or Sermorelin an approved medication?

Tesamorelin is an approved drug marketed as Egrifta, and Sermorelin was previously marketed as Geref before being discontinued in the United States. Those are regulated pharmaceutical products; the materials sold here are for laboratory research use only and are not those approved medicines.

COMPARISONS 6 MIN READ

Sermorelin vs Tesamorelin: A Research Comparison

Sermorelin and Tesamorelin both act on the GHRH receptor, so the comparison turns on length, stability, and regulatory history rather than target. Sermorelin is GRF(1-29), the shortest fragment that retains full GHRH activity; Tesamorelin is a longer, stabilized 44-residue analog. Their histories diverge sharply: Tesamorelin is an approved drug while Sermorelin was previously marketed and later discontinued. Both are supplied here as research-use-only materials, distinct from any approved product.

The core difference: fragment length and stability

Both compounds engage the same GHRH receptor, so the distinction is structural and pharmacokinetic. Sermorelin corresponds to the first 29 residues of GHRH, the shortest N-terminal segment that retains full receptor activity, which makes it the minimal active GHRH tool. Tesamorelin is a longer analog spanning the 44-residue GHRH sequence and carrying an N-terminal trans-3-hexenoyl modification studied for resistance to enzymatic degradation and a longer research half-life than native GHRH.

Structure and molecular profile

Sermorelin (molecular weight near 3357.9 g/mol) is a compact 29-residue GHRH fragment. Tesamorelin (molecular weight near 5135.9 g/mol) is the larger molecule, extending through residue 44 and carrying its stabilizing N-terminal group. Exact salt form and modification should be confirmed against each lot-matched Certificate of Analysis, since acylated analogs can vary by counter-ion.

Clinical and regulatory context

This pair is unusual in that both molecules have documented regulatory histories. Tesamorelin is an approved drug, marketed as Egrifta and indicated for HIV-associated lipodystrophy, and has been studied in human clinical research within growth hormone and lipid-metabolism endpoints. Sermorelin was previously marketed under the brand name Geref and used in growth-hormone-related clinical contexts before being discontinued in the United States. Those facts describe regulated or formerly regulated pharmaceutical products; the Sermorelin and Tesamorelin supplied here are research-use-only materials and are not those approved medicines.

How each is studied

Both are used to investigate GHRH-receptor agonism, pulsatile GH-secretion dynamics, and somatotroph signaling. Tesamorelin is additionally a common choice where the research question extends to lipid metabolism or visceral-adiposity endpoints, reflecting the area its approved counterpart was studied in. A protocol favors Sermorelin when a minimal, well-characterized active fragment is wanted, and Tesamorelin when a stabilized longer analog better fits the design.

All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.